Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators

Chest

Volumn 128, Issue 4, 2005, Pages 2604-2610

  Manios, Emmanuel G ^a   Kallergis, Eleftherios M ^a   Kanoupakis, Emmanuel M ^a   Mavrakis, Hercules E ^a   Kambouraki, Despina C ^a   Arfanakis, Dimitris A ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Ischemic cardiomyopathy; Natriuretic peptides; Risk stratification; Sudden cardiac death; Ventricular arrhythmogenesis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; NEUROHORMONE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARRHYTHMOGENESIS; ARTICLE; BLOOD SAMPLING; CARDIOMYOPATHY; CARDIOVERSION; CLINICAL ARTICLE; DEFIBRILLATOR; FEMALE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; IMPLANTATION; ISCHEMIC HEART DISEASE; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN DEATH; VENOUS BLOOD;

EID: 27144440322     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2604     Document Type: Article

References (36)

1. Ray IB, Reddy VY. Implanted defibrillators and primary prevention of sudden cardiac death: where are we today? Int J Cardiol 2005; 98:15-20
2. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation 2004; 109:2685-2691
3. Huikuri HV, Makikallio TH, Raatikainen MJ, et al. Prediction of sudden cardiac death: appraisal of the studies and methods assessing the risk of sudden arrhythmic death. Circulation 2003; 108:110-115
4. Maisel AS. B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. Rev Cardiovasc Med 2001; 2(suppl 2):S13-S18
5. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105:2392-2397
6. Gardnera RS, Ozalp F, Murdaya AJ, et al. N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24:1735-1743
7. Koglin J, Pehlivanli S, Schwaiblamir M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38:1934-1941
8. Harrison A, Morrison LK, Krishnaswainy P, et al. B-type natriuretic peptide (BNP) predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39:131-138
9. Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the β-blocking era. J Am Coll Cardiol 2004; 43:757-763
10. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110:3206-3212
11. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913-2918
12. Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110:128-134
13. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997; 47:287-296
14. Hansen DE, Craig CS, Hndeghem LM. Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation 1990; 81:1094-1105
15. Franz MR, Cima R, Wang D. Electrophysiological effects of myocardial stretch and mechanical determinants for stretch-activated arrhythmias. Circulation 1992; 86:968-978
16. Reiter MJ. Effects of mechanoelectrical feedback: influence among patients with congestive heart failure. Cardiovasc Res 1996; 32:44-51
17. Zhu WX, Johnson SB, Brandt R, et al. Impact of volume loading and load reduction on ventricular refractoriness and conduction properties in canine congestive heart failure. J Am Coll Cardiol 1997; 30:825-833
18. MADIT Executive Committee. Multicenter Automatic Defibrillator Implantation Trial (MADIT): design and clinical protocol. Pacing Clin Electrophysiol 1991; 14:920-927
19. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-1583
20. Kuck KH, Cappato R, Seibels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748-754
21. Connolly SJ, Gent M, Roberts R, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable defibrillator against amiodarone. Circulation 2000; 101: 1297-1302
22. Moss AJ, Hall WJ, Cannom DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335:1933-1940
23. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341:1882-1890
24. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 2000; 342:1937-1945
25. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883
26. Rosenqvist M, Beyer T, Block M, et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators [published correction appears in Circulation 1998; 98:2647]. Circulation 1998; 98:663-670
27. Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: can we afford to do it? (Can we afford not to?) Circulation 2001; 104:1564-1570
28. Sears SF, Todaro JF, Urizar G, et al. Assessing the psychosocial impact of the ICD: a national survey of implantable cardioverter defibrillator health care providers. Pacing Clin Electrophysiol 2000; 23:939-945
29. Richards MA, Nicholls GM, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929
30. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328
31. Franz MR. Mechano-electrical feedback in ventricular myocardium. Cardiovasc Res 1996; 32:15-24
32. Tavazzi L, Volpi A. Remarks about postinfarction prognosis in light of the experience with the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) trials. Circulation 1997; 95:1341-1345
33. Nanthakumnr K, Epstein AE, Kay NG, et al. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 2004; 44:2166-2172
34. Weber H, Allikmets K, Kornfeld G. Treating electrical instability in sudden cardiac death survivors: are we looking at the right side of the coin? Eur Heart J 2004; 25:623-625
35. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003; 138:445-452
36. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. New York, NY: WB Saunders Publishing, 1997; 742-779